Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

2.660 -0.090 (-3.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 85,443
Open 2.700
Bid (Size) 2.500 (2)
Ask (Size) 2.850 (4)
Prev. Close 2.750
Today's Range 2.520 - 2.850
52wk Range 2.090 - 5.670
Shares Outstanding 20,595,503
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Syros to Participate in Upcoming Investor Conferences
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire

Performance

YTD
-24.86%
-24.86%
1 Month
+12.71%
+12.71%
3 Month
-32.49%
-32.49%
6 Month
-28.11%
-28.11%
1 Year
-33.50%
-33.50%

More News

Read More
Preview: Syros Pharmaceuticals's Earnings
Via Benzinga
Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Earnings Outlook For Syros Pharmaceuticals
Via Benzinga
Syros Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Syros Pharmaceuticals's Earnings Outlook
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
From Syros Pharmaceuticals
Via Business Wire
Pfizer To Terminate Development Pact With Syros Pharmaceuticals For Novel Therapies For Two Blood Disorders
Via Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Sidoti Events, LLC's Virtual June Small-Cap Conference
Via ACCESSWIRE
Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
From Syros Pharmaceuticals
Via Business Wire
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Present at JMP Securities 2023 Life Sciences Conference
From Syros Pharmaceuticals
Via Business Wire
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.